Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11397MR)

This product GTTS-WQ11397MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11397MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ166MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ11801MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ1579MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ1638MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ7204MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ6430MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ2499MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ14504MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RYI-018
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW